Hemispherx Biopharma Inc., of Philadelphia, said preclinical data published in American Journal of Pathology showed that Toll-like receptor (TLR) 3-targeting Ampligen displayed a discordance between rodent and human inflammatory responses, unlike other TLR stimulators that trigger pro-inflammatory cascades that can lead to significant side effects in patients.